

REMARKS**INTRODUCTION:**

In accordance with the foregoing, claims 5, 7, 8, 12, 16, 17, 18, 19, 48 and 49 have been cancelled without prejudice or disclaimer, claims 1, 10, 13, 14, and 15 have been amended. No new matter is being presented, and approval and entry are respectfully requested.

Claims 1, 10, and 13-15 are pending and under consideration. Reconsideration is respectfully requested.

ENTRY OF RESPONSE UNDER 37 C.F.R. §1.116:

Applicants request entry of this Rule 116 Response and Request for Reconsideration because:

(a) at least certain of the rejected claims have been canceled thereby at least reducing the issues for appeal;

(b) it is believed that the amendments of claims 1, 10, 13, 14, and 15 put this application into condition for allowance;

(c) the amendments were not earlier presented because the Applicants believed in good faith that the cited prior art did not disclose the present invention as previously claimed;

(d) the amendments of claims 1, 10, 13, 14, and 15 should not entail any further search by the Examiner since no new features are being added or no new issues are being raised; and/or

(e) the amendments do not significantly alter the scope of the claims and place the application at least into a better form for appeal. No new features or new issues are being raised.

The Manual of Patent Examining Procedures sets forth in §714.12 that "[a]ny amendment that would place the case either in condition for allowance or in better form for appeal may be entered." (Underlining added for emphasis) Moreover, §714.13 sets forth that "[t]he Proposed Amendment should be given sufficient consideration to determine whether the claims are in condition for allowance and/or whether the issues on appeal are simplified." The Manual of Patent Examining Procedures further articulates that the reason for any non-entry should be explained expressly in the Advisory Action.

REJECTION UNDER 35 U.S.C. §103:

A. In the Office Action, at pages 2-3, numbered paragraphs 3-5, claims 1, 5, 7, 16, 48 and 49 were rejected under 35 U.S.C. §103(a) as being unpatentable over Fong et al., as evidenced by Tarumi et al. The reasons for the rejection are set forth in the Office Action and therefore not repeated. The rejection is traversed and reconsideration is requested.

B. In the Office Action, at page 3, numbered paragraph 6, claims 17-18 were rejected under 35 U.S.C. §103(a) as being unpatentable over Fong et al., as evidenced by Tarumi et al. and in view of Canon. The reasons for the rejection are set forth in the Office Action and therefore not repeated. The rejection is traversed and reconsideration is requested.

C. In the Office Action, at pages 3-4, numbered paragraph 8, claim 19 was rejected under 35 U.S.C. §103(a) as being unpatentable over Fong et al., as evidenced by Tarumi et al. and in view of Sato. The reasons for the rejection are set forth in the Office Action and therefore not repeated. The rejection is traversed and reconsideration is requested.

With respect to A, B and C above, claim 1 has been amended to include the features of claims 8 and 12. Claims 5, 7, 8, 12, 16, 17, 18, 19, 48 and 49 have been cancelled. Hence, in accordance to the Office Action, under Allowable Subject Matter, claim 1 is in allowable form. Since claims 10 and 13-15 depend from amended claim 1, claims 10 and 13-15 are submitted to be allowable under 35 U.S.C. §103(a) over the cited references for at least the reasons amended claim 1 is allowable 35 U.S.C. §103(a) over the cited references.

It should be noted that the reference Fong discloses a polyfunctional (meth) acrylate having two benzene rings in one molecule (in col. 10, line 24) and a polyfunctional urethane-modified (meth) acrylate (in col. 12, lines 21-22). However, the feature of the Fong invention is in using a brominated monomer, and the Fong invention does not disclose poly functional (meth) acrylate expressed by the Formula (1) as is recited in claim 1 of the present invention.

The Tarumi reference fails to disclose either the glass lens to be the base member or the polyfunctional urethane-modified (meth) acrylate.

The Canon reference fails to disclose either the polyfunctional (meth) acrylate comprising two benzene rings in one molecule or the polyfunctional (meth) acrylate disclosed in the claims of the present invention.

ALLOWABLE SUBJECT MATTER:

In the Office Action at page 4, the Examiner indicated that claims 8, 10, and 12-15 were objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

The subject matter of claims 8 and 12 has been incorporated into amended independent claim 1, and claims 8 and 12 have been cancelled. Hence, amended claim is now submitted to be in allowable form. Since claims 10 and 13-15 depend from amended claim 1, claims 10 and 13-15 are submitted to be allowable for at least the same reasons as amended claim 1 is allowable.

CONCLUSION:


In accordance with the foregoing, it is respectfully submitted that all outstanding objections and rejections have been overcome and/or rendered moot, and further, that all pending claims patentably distinguish over the prior art. Thus, there being no further outstanding objections or rejections, the application is submitted as being in condition for allowance which action is earnestly solicited. At a minimum, this Amendment should be entered at least for purposes of Appeal as it either clarifies and/or narrows the issues for consideration by the Board.

If the Examiner has any remaining issues to be addressed, it is believed that prosecution can be expedited and possibly concluded by the Examiner contacting the undersigned attorney for a telephone interview to discuss any such remaining issues.

If there are any underpayments or overpayments of fees associated with the filing of this Amendment, please charge and/or credit the same to our Deposit Account No. 19-3935.

Respectfully submitted,

STAAS & HALSEY LLP

Date: November 21, 2005 By: 
Darleen J. Stockley
Registration No. 34,257

1201 New York Avenue, N.W.
Suite 700
Washington, D.C. 20005
Telephone: (202) 434-1500
Facsimile: (202) 434-1501